← Human Trials & Peer-Reviewed Studies
CGRP and PACAP-38 play an important role in diagnosing pediatric migraine
Plain-language guide to PMID 35698032 (2022): clinical trial study of CGRP (Calcitonin Gene-Related Peptide) and PACAP in 38 children, migraine.
Key Facts
- PMID
- 35698032
- Journal
- The journal of headache and pain
- Year
- 2022
- Study type
- Clinical Trial
- Authors
- Liu J et al. (4 authors)
- DOI
- 10.1186/s10194-022-01435-7
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of CGRP (Calcitonin Gene-Related Peptide) and PACAP in the context of migraine, published as a clinical trial.
The researchers also performed logistic regression and receiver operating characteristic curve (ROC) analyses to evaluate the diagnostic value of CGRP and PACAP-38 in pediatric migraine.
Why It Was Studied
The researchers prospectively investigated CGRP and PACAP-38 plasma levels in children with migraine during ictal and interictal periods and compared the results between migraine patients with aura and without aura.
The researchers were the first to explore the diagnostic value of a combination of CGRP and PACAP-38.
Who Took Part
The abstract describes 38 children taking part.
The age groups tagged for this paper are children and adults.
Seventy-six migraine patients aged 4-18 years and seventy-seven age-matched healthy children were included in the study.
How the Study Was Run
Plasma vasoactive peptides were measured using the enzyme-linked immunosorbent assay (ELISA).
Differences and correlations of groups were analyzed using the independent samples t-test, analysis of variance (ANOVA), Mann-Whitney U test, and multiple linear regression.
What Was Measured
The researchers prospectively investigated CGRP and PACAP-38 plasma levels in children with migraine during ictal and interictal periods and compared the results between migraine patients with aura and without aura.
PubMed files the paper under topics including Calcitonin Gene-Related Peptide, Migraine Disorders and Pituitary Adenylate Cyclase-Activating Polypeptide.
Author keywords: Diagnostic value, Logistic regression, Pediatric migraine, Pituitary adenylate cyclase-activating polypeptide-38 and ROC curve.
What This Means in Plain Language
This is a clinical trial of CGRP (Calcitonin Gene-Related Peptide) and PACAP in 38 children in people with migraine.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2022 (The journal of headache and pain), a journal based in England.
More context: the CGRP (Calcitonin Gene-Related Peptide) compound page and the PACAP compound page, Migraine research.
Our Notes on the Compounds
CGRP (Calcitonin Gene-Related Peptide): A 37-amino-acid neuropeptide that widens blood vessels and is involved in migraine; given in research provocation studies.
PACAP: Pituitary adenylate cyclase-activating polypeptide, a 38-amino-acid neuropeptide studied in migraine provocation research.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.